Corcept Therapeutics Inc. (CORT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.28 (+0.47%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Key Insights

Critical company metrics and information
  • Share Price

    $59.26
  • Market Cap

    $6.21 Billion
  • Total Outstanding Shares

    104.78 Million Shares
  • Total Employees

    352
  • Dividend

    No dividend
  • IPO Date

    April 14, 2004
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.corcept.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$25.49 Million
Net Cash Flow From Operating Activities, Continuing$144.65 Million
Net Cash Flow$25.49 Million
Net Cash Flow From Investing Activities, Continuing$-96.15 Million
Net Cash Flow From Financing Activities, Continuing$-23.02 Million
Net Cash Flow From Financing Activities$-23.02 Million
Net Cash Flow From Operating Activities$144.65 Million
Net Cash Flow From Investing Activities$-96.15 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$24.52 Million
Basic Average Shares$308.91 Million
Basic Earnings Per Share$1.36
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$735,000.00
Gross Profit$618.75 Million
Net Income/Loss Attributable To Parent$141.82 Million
Costs And Expenses$485.20 Million
Net Income/Loss$141.82 Million
Cost Of Revenue$9.80 Million
Diluted Average Shares$334.57 Million
Income/Loss From Continuing Operations Before Tax$166.34 Million
Operating Income/Loss$143.36 Million
Benefits Costs and Expenses$462.21 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$1.26
Revenues$628.55 Million
Net Income/Loss Available To Common Stockholders, Basic$140.47 Million
Research and Development$231.29 Million
Preferred Stock Dividends And Other Adjustments$735,000.00
Nonoperating Income/Loss$22.98 Million
Income Tax Expense/Benefit, Deferred$-40.01 Million
Selling, General, and Administrative Expenses$244.10 Million
Income/Loss From Continuing Operations After Tax$141.82 Million
Operating Expenses$475.39 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$126.22 Million
Inventory$8.05 Million
Noncurrent Liabilities$19.21 Million
Noncurrent Assets$317.28 Million
Current Assets$466.98 Million
Liabilities$145.42 Million
Other Non-current Assets$314.35 Million
Other Current Assets$453.11 Million
Accounts Payable$18.58 Million
Equity Attributable To Parent$638.84 Million
Liabilities And Equity$784.26 Million
Equity$638.84 Million
Prepaid Expenses$5.82 Million
Assets$784.26 Million
Fixed Assets$2.93 Million
Other Current Liabilities$107.63 Million
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.